Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.51 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | JAK1 | P23458 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | STK4 | Q13043 | 2/20 | 0.45 |
| ▸ | STK3 | Q13188 | 2/20 | 0.45 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.45 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494544 | 0.92 | BRD4 (0.58) | SYKBRD4JAK3SIK2SIK3 | |
| SCHEMBL1743372 | 0.90 | SYK (0.47) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL3495928 | 0.89 | SYK (0.65) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL13248984 | 0.85 | SYK (0.46) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL1741119 | 0.84 | BRD4 (0.48) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL3495622 | 0.84 | BRD4 (0.56) | SYKBRD4MAP4K3PAK1 | |
| SCHEMBL13248971 | 0.82 | SYK (0.46) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL3494973 | 0.82 | SYK (0.46) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL1743522 | 0.82 | BRD4 (0.46) | SYKBRD4JAK1JAK2JAK3 | |
| SCHEMBL3494964 | 0.82 | BRD4 (0.50) | SYKBRD4SIK2SIK3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575165-B2 | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2387402-A2 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8038799-B2 | Substrate processing apparatus and substrate processing method | KURITA WATER INDUSTRIES LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083240-A2 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SYK 460/4885BRD4 1173/4885JAK1 292/4885 |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | IL2, IL17A, IL23R | SYK 1196/4885BRD4 664/4885JAK1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.